Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal.
Metastatic squamous cell carcinoma (SCC) of the anal canal is rare with limited data regarding treatment. Epidermal growth factor receptor (EGFR) expression has been observed in SCC of the anal canal and Kristen rat sarcoma vial oncogene (KRAS) mutations are rare. EGFR monoclonal antibodies, cetuximab and panitumumab, represent a potential option in this patient population. We report a metastatic SCC of the anal canal patient treated with cetuximab in combination with cisplatin plus 5-Fluorouracil (5-FU) that had a dramatic response.
1 Pharmacy Clinical Programs, 2 Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, USA.
Jane E
JE
Rogers
1 Pharmacy Clinical Programs, 2 Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, USA.
Ninoska N
NN
Silva
1 Pharmacy Clinical Programs, 2 Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, USA.
Cathy
C
Eng
Cetuximab; anal cancer; epidermal growth factor receptor (EGFR) inhibitors